BD-pTau 217 and Alpha-Synuclein Biomarker Detection On-Demand Webinar
Watch this on-demand webinar to learn how BD-pTau 217 and alpha-synuclein biomarker detection can support neurodegenerative disease research, including Alzheimer’s disease, Parkinson’s disease, and related synucleinopathies.
Reliable measurement of blood-based neurodegenerative biomarkers remains a significant challenge, particularly for low-abundance targets such as brain-derived pTau 217, total alpha-synuclein, and pS129-alpha-synuclein. In this webinar, Dr. Tracy Liu, Director of Product Management at Spear Bio, discusses how advances in ultra-sensitive immunoassay technology are helping researchers generate more consistent and interpretable biomarker data across healthy and disease populations.
Complete the form to access the on-demand webinar
What you will learn:
In this webinar, you’ll learn how ultra-sensitive immunoassay technology can help researchers:
- Detect BD-pTau 217 for Alzheimer’s disease pathology research
- Measure total alpha-synuclein and pS129-alpha-synuclein for Parkinson’s disease and synucleinopathy research
- Support early detection, disease stratification, and longitudinal monitoring applications
- Explore paired total and phosphorylated alpha-synuclein measurements, including ratio-based analyses
- Address analytical considerations for ultra-low-abundance biomarker detection
- Generate more reliable biomarker data across healthy individuals and disease-stage cohorts
Featured Speaker:
Dr. Tracy Liu
Director, Product Management, Spear Bio
Dr. Tracy Liu leads product strategy and development at Spear Bio, bringing deep experience in biomarker assay commercialization, ultra-sensitive detection technologies, and life science product management.
Before joining Spear Bio, Tracy served as Associate Director of Product Marketing at Quanterix, where she led strategic marketing initiatives for the Simoa® ultra-sensitive biomarker detection platform. She has also held senior roles in product management, marketing, and technical service at Bio-Techne, Inscripta, and Agilent Technologies.
Tracy holds a PhD in Cell and Molecular Biology from the University of Toledo and is passionate about translating complex life science technologies into impactful products that empower biomarker discovery and clinical research.
Ultra-Sensitive BD-pTau 217 Detection for Alzheimer’s Research
BD-pTau 217 is an important biomarker for Alzheimer’s disease research, with potential applications across early detection, disease stratification, therapeutic monitoring, and longitudinal studies.
Spear Bio’s ultra-sensitive immunoassay technology is designed to help researchers measure challenging low-abundance biomarkers in blood with confidence. By supporting reliable BD-pTau 217 detection, Spear Bio helps advance research into Alzheimer’s disease pathology and progression.
Alpha-Synuclein Detection for Parkinson’s Disease Research
Total alpha-synuclein and pS129-alpha-synuclein are key biomarkers for Parkinson’s disease and related synucleinopathies. Measuring both total and phosphorylated alpha-synuclein on the same platform may enable deeper biological insight, including ratio-based analyses that support research into disease progression and patient stratification.
Spear Bio’s alpha-synuclein assays are designed to support sensitive and consistent detection of these biomarkers in neurodegenerative disease research.
Explore Alpha-Synuclein Assays
Contact Spear Bio About Neurodegenerative Biomarker Detection
Interested in applying Spear Bio’s assays to your research?
Whether your team is working in Alzheimer’s disease, Parkinson’s disease, synucleinopathies, translational research, or clinical development, Spear Bio can help you evaluate assay fit for your study goals.
Connect with our team to discuss:
- BD-pTau 217 detection applications
- Total alpha-synuclein and pS129-alpha-synuclein detection
- Sample type and volume considerations
- Study design and longitudinal monitoring needs
- Platform fit for biomarker research workflows
